J B Chemicals & Pharmaceuticals : Presentation at JP Morgan Healthcare Conference, SFO US

January 10, 2023

BSE Ltd.

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Subject: Presentation at JP Morgan Healthcare Conference, SFO US

Enclosed please find the presentation proposed to be made by the Company at the JP Morgan Healthcare Conference on Tuesday, January 10, 2023. The presentation is for your records.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep

Anil

Phadnis

Digitally signed by Sandeep Anil Phadnis DN: c=IN, o=Personal, 2.5.4.20=3cf6eb0200f976a58369e39fde8b8 876481484d38598145f6e21f446bb743f2e, postalCode=411038, st=Maharashtra, serialNumber=cc500fdd638e71336fc58b20 4e2ba05ea7c4ade49b8fe438e8f254c300de c735, cn=Sandeep Anil Phadnis

Date: 2023.01.10 15:33:18 +05'30'

Sandeep Phadnis

Vice President - Secretarial

& Company Secretary

JB Pharma

(JB Chemicals & Pharmaceuticals

Ltd)

NSE : JBCHEPHARM

BSE : JBCHEPHARM

JP Morgan Healthcare Conference, SFO

Tuesday, January 10, 2023

www.jbpharma.com		jbpharma/
Jan 2023	JB Pharma	1

Disclaimer

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management JB Chemicals & Pharmaceuticals Limited ("Company" or "JB Pharma" or "JB Chemicals & Pharmaceuticals Limited "), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from. This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Jan 2023

JB Pharma

2

Jan 2023

JB Pharma

3

Corporate Snapshot

46	Years of operations with
consistent track record
	across multiple businesses
$2bn	Market Cap on INR 152
billion (USD 1.85 bn)#
Sales : INR 24000 mn in
	FY 22
Top 5	Global manufacturer of
medicated/herbal
lozenges representing a
	substantial opportunity

Multi-dosage formulation

• plants with key global regulatory approvals/compliances

Brands among top 300

• data), contributing over 60% of domestic formulations revenuesbrands (IQVIA MAT Nov'22

Growth in chronic

24% therapies* in the domestic formulations business

Strong India field force with

2500+ therapy-focused segmentation

ROCE with consistent cash **22% flow generation generating

good returns

Increasing Share of the Domestic

Revenue

54%	56%		52%	46%
46%	44%		48%	54%
	FY20	FY21		FY22	H1 FY23
	Domestic Formulations	International Biz
				42%
		24%	29%		22%
15%
		25%
			19%	18%
		13%
	10%
	FY18	FY19	FY20	FY21	FY22

* CAGR over FY20-FY22 IQVIA MAT Oct'22	# Market Cap	** ROCE = EBIT/(Net Worth + Debt - Mutual Fund
*** MAT - Moving Average Total	as on 6th Jan'23	Investments)
Jan 2023		JB Pharma

ROE (%) ROCE (%)

4